Germline mutations in RAD51D confer susceptibility to ovarian cancer

Overview of attention for article published in Nature Genetics, August 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog
policy: 1 policy source
twitter: 11 X users

patent: 21 patents
facebook: 2 Facebook pages
wikipedia: 2 Wikipedia pages
guideline: 4 clinical guideline sources

Readers on

mendeley: 350 Mendeley
citeulike: 3 CiteULike

So far, Altmetric has seen 12 X posts from 11 X users, with an upper bound of 51,699 followers.

@PaulieNaz This is 2011 research https://t.co/x81hF53YYP but states "we show that cells deficient in RAD51D are sensitive to treatment with a PARP inhibitor, suggesting a possible therapeutic approach for cancers arising in RAD51D mutation carriers. "

Germline mutations in RAD51D confer susceptibility to ovarian cancer. http://t.co/Cf56LOYo

Nature Genetics - Germline mutations in RAD51D confer susceptibility to ovarian cancer http://t.co/KfKLSmw

How long until it's patented?: Germline mutations in RAD51D confer susceptibility to ovarian cancer http://t.co/ZnsBTZN

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.